Free Trial
→ Man who predicted $100K Bitcoin sees a huge run coming for another coin … (From Weiss Ratings) (Ad) Buy RARE Stock  Free RARE Stock Alerts

Ultragenyx Pharmaceutical (RARE) Financials

Ultragenyx Pharmaceutical logo
$35.08 -0.58 (-1.63%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$35.10 +0.02 (+0.06%)
As of 04:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Ultragenyx Pharmaceutical

Annual Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -569 -607 -707 -454 -187 -403 -198 -302 -246 -146
Consolidated Net Income / (Loss)		 -569 -607 -707 -454 -187 -403 -198 -302 -246 -146
Net Income / (Loss) Continuing Operations		 -569 -607 -707 -454 -187 -403 -198 -302 -246 -146
Total Pre-Tax Income 		-568 -608 -702 -453 -185 -399 -197 -318 -246 -146
Total Operating Income		 -536 -569 -649 -382 -330 -424 -371 -329 -248 -148
Total Gross Profit		 484 389 335 335 265 95 50 2.61 0.13 0.00
Total Revenue		 560 434 363 351 271 104 51 2.61 0.13 0.00
Operating Revenue		 560 434 363 351 271 104 51 2.61 0.13 0.00
Total Cost of Revenue		 77 45 28 16 6.13 9.01 1.15 0.00 0.00 0.00
Operating Cost of Revenue		 77 45 28 16 6.13 9.01 1.15 0.00 0.00 0.00
Total Operating Expenses		 1,019 958 984 717 595 519 422 332 248 148
Selling, General & Admin Expense		 322 310 278 220 183 162 128 100 65 33
Research & Development Expense		 698 648 706 497 412 357 294 232 183 115
Total Other Income / (Expense), net		 -32 -39 -53 -71 145 25 174 11 2.17 2.12
Interest Expense		 63 66 43 29 33 1.14 0.00 0.00 - -
Interest & Investment Income		 35 27 -8.23 -40 177 27 9.54 4.07 3.79 2.32
Other Income / (Expense), net		 -3.96 -0.34 -1.57 -1.69 0.61 -0.79 165 6.53 -1.62 -0.20
Income Tax Expense		 1.60 -1.83 5.70 1.04 1.21 3.28 0.51 -16 0.04 0.00
Basic Earnings per Share		 ($6.29) ($8.25) ($10.12) ($6.70) ($3.07) ($7.12) ($3.97) ($7.12) ($6.21) ($3.96)
Weighted Average Basic Shares Outstanding		 90.54M 73.54M 69.91M 67.80M 60.85M 56.58M 49.78M 42.45M 39.59M 36.78M
Diluted Earnings per Share		 ($6.29) ($8.25) ($10.12) ($6.70) ($3.07) ($7.12) ($3.97) ($7.12) ($6.21) ($3.96)
Weighted Average Diluted Shares Outstanding		 90.54M 73.54M 69.91M 67.80M 60.85M 56.58M 49.78M 42.45M 39.59M 36.78M
Weighted Average Basic & Diluted Shares Outstanding		 92.50M 82.34M 70.22M 67.80M 60.85M 56.58M 49.78M 42.45M 39.59M 36.78M

Quarterly Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -151 -133 -134 -132 -171 -123 -160 -160 -164 -152 -245
Consolidated Net Income / (Loss)		 -151 -133 -134 -132 -171 -123 -160 -160 -164 -152 -245
Net Income / (Loss) Continuing Operations		 -151 -133 -134 -132 -171 -123 -160 -160 -164 -152 -245
Total Pre-Tax Income 		-150 -133 -133 -131 -170 -127 -159 -159 -163 -153 -239
Total Operating Income		 -143 -122 -132 -116 -165 -122 -145 -148 -154 -146 -225
Total Gross Profit		 111 148 118 126 91 115 87 98 88 98 82
Total Revenue		 139 165 139 147 109 127 98 108 100 103 91
Operating Revenue		 139 165 139 147 109 127 98 108 100 103 91
Total Cost of Revenue		 29 17 21 21 18 12 11 9.91 12 5.32 8.63
Operating Cost of Revenue		 29 17 21 21 18 12 11 9.91 12 5.32 8.63
Total Operating Expenses		 254 270 250 242 257 237 232 246 242 244 307
Selling, General & Admin Expense		 88 82 80 81 78 77 75 81 77 73 70
Research & Development Expense		 166 188 170 162 178 161 157 165 166 171 237
Total Other Income / (Expense), net		 -6.83 -11 -1.23 -14 -4.88 -4.84 -14 -11 -9.37 -7.66 -14
Interest Expense		 14 16 16 16 16 17 18 15 16 16 15
Interest & Investment Income		 6.67 8.00 11 3.41 13 10 4.46 6.23 5.96 8.04 1.86
Other Income / (Expense), net		 0.84 -3.61 3.08 -1.83 -1.61 2.04 -0.70 -1.99 0.31 0.18 -1.11
Income Tax Expense		 1.31 -0.02 0.30 0.86 0.46 -3.70 0.65 0.73 0.50 -1.45 6.29
Basic Earnings per Share		 ($1.57) ($1.34) ($1.40) ($1.52) ($2.03) ($1.44) ($2.23) ($2.25) ($2.33) ($2.17) ($3.50)
Weighted Average Basic Shares Outstanding		 96.29M 90.54M 95.49M 86.58M 84.29M 73.54M 71.66M 70.90M 70.37M 69.91M 70.05M
Diluted Earnings per Share		 ($1.57) ($1.34) ($1.40) ($1.52) ($2.03) ($1.44) ($2.23) ($2.25) ($2.33) ($2.17) ($3.50)
Weighted Average Diluted Shares Outstanding		 96.29M 90.54M 95.49M 86.58M 84.29M 73.54M 71.66M 70.90M 70.37M 69.91M 70.05M
Weighted Average Basic & Diluted Shares Outstanding		 94.54M 92.50M 92.34M 92.17M 83.13M 82.34M 82.11M 71.49M 70.81M 70.22M 70.11M

Annual Cash Flow Statements for Ultragenyx Pharmaceutical

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -35 82 -172 -417 290 321 13 -62 69 69
Net Cash From Operating Activities		 -414 -475 -380 -339 -132 -345 -291 -254 -161 -106
Net Cash From Continuing Operating Activities		 -414 -475 -384 -339 -132 -345 -291 -254 -161 -106
Net Income / (Loss) Continuing Operations		 -569 -607 -707 -454 -187 -403 -198 -302 -246 -146
Consolidated Net Income / (Loss)		 -569 -607 -707 -454 -187 -403 -198 -302 -246 -146
Depreciation Expense		 36 26 18 13 12 8.54 20 5.83 3.42 1.38
Amortization Expense		 -13 -13 2.70 6.61 0.85 -6.21 -2.64 1.71 4.84 5.64
Non-Cash Adjustments To Reconcile Net Income		 118 134 246 101 3.14 72 -85 61 50 25
Changes in Operating Assets and Liabilities, net		 14 -15 56 -5.74 38 -17 -25 -20 26 7.74
Net Cash From Investing Activities		 -18 168 -292 -195 -179 -13 -33 55 91 -292
Net Cash From Continuing Investing Activities		 -18 168 -292 -195 -179 -13 -33 55 91 -292
Purchase of Property, Plant & Equipment		 -7.49 -44 -116 -73 -44 -25 -4.08 -2.79 -10 -4.96
Acquisitions		 -13 -2.50 -105 0.00 -37 -14 0.00 -143 0.00 0.00
Purchase of Investments		 -409 -526 -615 -1,012 -813 -693 -510 -230 -442 -624
Sale and/or Maturity of Investments		 413 746 545 891 721 719 310 432 544 338
Other Investing Activities, net		 -2.44 -5.05 -0.84 -0.94 -5.56 0.00 0.00 - - -1.54
Net Cash From Financing Activities		 399 388 501 119 600 679 337 136 139 468
Net Cash From Continuing Financing Activities		 399 388 501 119 600 679 337 136 139 468
Repayment of Debt		 0.00 -0.03 -0.56 -0.49 -0.24 0.00 0.00 -4.94 0.00 0.00
Issuance of Common Equity		 399 388 11 119 601 365 337 141 139 468
Other Financing Activities, net		 0.00 0.00 491 0.00 0.00 314 0.00 0.00 - -
Effect of Exchange Rate Changes		 -2.53 0.46 -1.08 -1.19 1.12 -0.17 - 0.53 -0.07 0.00

Quarterly Cash Flow Statements for Ultragenyx Pharmaceutical

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -45 24 -330 368 -97 141 -29 16 -46 -259 234
Net Cash From Operating Activities		 -166 -80 -67 -77 -191 -84 -118 -116 -157 -90 -95
Net Cash From Continuing Operating Activities		 -166 -80 -67 -77 -191 -84 -118 -116 -157 -94 -95
Net Income / (Loss) Continuing Operations		 -151 -133 -134 -132 -171 -123 -160 -160 -164 -152 -245
Consolidated Net Income / (Loss)		 -151 -133 -134 -132 -171 -123 -160 -160 -164 -152 -245
Depreciation Expense		 8.99 9.08 8.76 8.86 8.85 8.22 7.19 5.36 5.24 4.96 4.69
Amortization Expense		 -1.73 -2.81 -3.12 -2.95 -3.76 -3.95 -2.68 -3.22 -2.99 -1.65 0.97
Non-Cash Adjustments To Reconcile Net Income		 34 25 30 32 31 22 34 34 43 36 122
Changes in Operating Assets and Liabilities, net		 -57 23 31 16 -56 13 2.80 7.16 -38 18 22
Net Cash From Investing Activities		 120 103 -276 61 94 -107 64 99 111 -172 -162
Net Cash From Continuing Investing Activities		 120 103 -276 61 94 -107 64 99 111 -172 -162
Purchase of Property, Plant & Equipment		 -1.32 -0.65 -1.62 -2.01 -3.21 -1.60 -3.70 -14 -25 -27 -26
Acquisitions		 -15 - - -2.50 -10 - - -2.50 0.00 0.37 -75
Purchase of Investments		 0.00 -16 -367 -3.37 -22 -222 -139 -103 -62 -199 -211
Sale and/or Maturity of Investments		 137 119 94 68 132 116 208 220 202 54 151
Other Investing Activities, net		 -0.78 -0.13 -0.20 -0.04 -2.07 -0.27 -0.43 -0.40 -3.95 -0.60 -0.18
Net Cash From Financing Activities		 0.16 3.19 11 385 -0.06 331 25 33 -0.72 1.88 492
Net Cash From Continuing Financing Activities		 0.16 3.19 11 385 -0.06 331 25 33 -0.72 1.88 492
Repayment of Debt		 0.00 - - - 0.00 - - -0.06 0.03 -0.12 -0.15
Issuance of Common Equity		 0.16 3.19 11 385 -0.06 331 25 33 -0.75 2.00 1.07
Effect of Exchange Rate Changes		 1.45 -2.47 1.28 -0.65 -0.68 1.10 -0.72 -0.14 0.21 1.35 -1.08

Annual Balance Sheets for Ultragenyx Pharmaceutical

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 1,503 1,491 1,545 1,522 1,760 1,135 720 491 541 560
Total Current Assets		 817 732 884 857 1,295 851 522 270 402 450
Cash & Equivalents		 174 214 133 308 714 434 113 100 161 94
Short-Term Investments		 436 364 615 433 488 322 346 134 219 343
Accounts Receivable		 122 73 40 28 23 33 13 5.17 0.00 -
Inventories, net		 45 34 27 16 13 12 7.07 0.76 0.00 -
Prepaid Expenses		 40 48 - 72 58 51 43 29 20 13
Other Current Assets		 0.00 0.00 69 - - - - - - -
Plant, Property, & Equipment, net		 266 291 260 141 74 44 20 22 17 7.37
Total Noncurrent Assets		 420 468 402 525 391 240 177 199 122 102
Long-Term Investments		 135 200 149 294 11 5.17 0.00 9.98 118 99
Goodwill		 44 44 44 44 44 44 44 44 0.00 -
Intangible Assets		 178 166 160 131 131 129 129 142 0.00 -
Other Noncurrent Operating Assets		 63 58 48 55 205 62 3.51 3.41 1.84 0.60
Total Liabilities & Shareholders' Equity		 1,503 1,491 1,545 1,522 1,760 1,135 720 491 541 560
Total Liabilities		 1,241 1,216 1,193 600 605 482 111 107 67 28
Total Current Liabilities		 344 280 261 181 190 103 75 71 60 28
Accounts Payable		 39 42 43 17 13 13 12 8.89 5.36 2.94
Accrued Expenses		 241 196 205 146 108 83 62 62 55 25
Other Current Liabilities		 64 42 13 19 68 7.24 0.00 - - -
Total Noncurrent Liabilities		 897 935 932 418 416 378 36 36 6.39 0.56
Noncurrent Deferred & Payable Income Tax Liabilities		 30 30 32 33 33 33 31 31 0.00 -
Other Noncurrent Operating Liabilities		 867 905 900 385 382 345 4.76 5.12 6.39 0.56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 7.00 0.00 - - - - - - - -
Total Equity & Noncontrolling Interests		 255 275 352 923 1,154 654 609 383 474 531
Total Preferred & Common Equity		 255 275 352 923 1,154 654 609 383 474 531
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 255 275 352 923 1,154 654 609 383 474 531
Common Stock		 4,213 3,662 3,140 2,998 2,773 2,087 1,640 1,222 1,004 817
Retained Earnings		 -3,957 -3,388 -2,781 -2,074 -1,620 -1,433 -1,030 -833 -531 -285
Treasury Stock		 -3.59 -0.43 0.00 - - - - - - -
Accumulated Other Comprehensive Income / (Loss)		 -0.64 0.65 -6.57 -1.40 0.69 -0.15 -0.63 -5.68 0.91 -0.87
Other Equity Adjustments		 3.59 0.43 0.00 - - - - - - -

Quarterly Balance Sheets for Ultragenyx Pharmaceutical

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,312 1,538 1,618 1,307 1,238 1,311 1,383 1,618
Total Current Assets		 699 800 965 596 599 702 766 1,013
Cash & Equivalents		 127 151 481 112 73 102 86 392
Short-Term Investments		 367 471 283 300 370 450 544 497
Accounts Receivable		 99 93 106 100 79 71 43 31
Inventories, net		 46 43 40 36 32 28 27 22
Prepaid Expenses		 60 - - 0.00 46 51 67 71
Plant, Property, & Equipment, net		 261 272 279 285 297 289 278 235
Total Noncurrent Assets		 352 466 375 426 342 320 339 371
Long-Term Investments		 69 203 111 157 86 72 90 121
Goodwill		 44 44 44 44 44 44 44 44
Intangible Assets		 177 165 166 165 157 158 159 158
Other Noncurrent Operating Assets		 62 54 54 60 54 46 45 47
Total Liabilities & Shareholders' Equity		 1,312 1,538 1,618 1,307 1,238 1,311 1,383 1,618
Total Liabilities		 1,161 1,185 1,186 1,167 1,206 1,182 1,163 1,150
Total Current Liabilities		 292 285 273 246 254 244 218 227
Accounts Payable		 47 36 60 41 33 42 59 24
Accrued Expenses		 173 185 154 149 179 168 144 189
Other Current Liabilities		 71 64 59 55 42 35 15 15
Total Noncurrent Liabilities		 869 900 913 921 952 938 945 922
Noncurrent Deferred & Payable Income Tax Liabilities		 30 30 30 30 32 32 32 33
Other Noncurrent Operating Liabilities		 839 869 883 891 921 906 913 889
Redeemable Noncontrolling Interest		 7.00 7.00 - - - - - -
Total Equity & Noncontrolling Interests		 144 347 432 140 32 129 220 469
Total Preferred & Common Equity		 144 347 432 140 32 129 220 469
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 144 347 432 140 32 129 220 469
Common Stock		 4,253 4,169 4,123 3,699 3,298 3,237 3,169 3,108
Retained Earnings		 -4,108 -3,823 -3,690 -3,558 -3,264 -3,105 -2,945 -2,629
Treasury Stock		 -7.57 -3.56 -3.40 -3.33 -0.38 -0.38 -0.36 -
Accumulated Other Comprehensive Income / (Loss)		 -0.34 0.90 -1.10 -0.43 -2.24 -3.10 -3.97 -10
Other Equity Adjustments		 7.57 3.56 3.40 3.33 0.38 0.38 0.36 -

Annual Metrics And Ratios for Ultragenyx Pharmaceutical

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 29.01% 19.52% 3.39% 29.66% 161.32% 101.41% 1,871.48% 1,863.91% 0.00% 0.00%
EBITDA Growth		 7.08% 11.62% -73.16% -14.91% 25.14% -122.74% 39.74% -30.46% -71.28% -151.07%
EBIT Growth		 5.20% 12.44% -69.65% -16.36% 22.46% -105.65% 35.91% -29.16% -68.74% -144.89%
NOPAT Growth		 5.84% 12.28% -69.99% -15.64% 22.17% -14.22% -12.90% -32.63% -67.87% -160.20%
Net Income Growth		 6.17% 14.25% -55.81% -143.36% 53.67% -103.80% 34.60% -22.88% -68.85% -143.50%
EPS Growth		 23.76% 18.48% -51.04% -118.24% 56.88% -79.35% 44.24% -14.65% -56.82% -76.00%
Operating Cash Flow Growth		 12.77% -24.80% -12.33% -156.16% 61.72% -18.87% -14.47% -57.69% -51.90% -137.44%
Free Cash Flow Firm Growth		 10.62% -1,951.27% 89.93% 23.81% -581.75% 84.80% 31.92% -158.66% -54.59% -170.01%
Invested Capital Growth		 3.78% 7.82% -388.14% -93.35% 45.93% -171.47% 7.35% 603.14% -270.74% -126.75%
Revenue Q/Q Growth		 7.17% 5.86% 5.81% -2.27% 26.01% 22.91% 36.78% 1,186.70% 3.91% 0.00%
EBITDA Q/Q Growth		 -0.76% 4.53% -7.66% -1.48% 0.44% -1.26% 3.92% -8.81% -7.42% -37.13%
EBIT Q/Q Growth		 -1.10% 4.28% -6.99% -1.91% -0.45% -0.95% 3.89% -8.96% -6.86% -36.06%
NOPAT Q/Q Growth		 -0.04% 3.98% -7.11% -1.73% -0.50% -0.98% 1.72% -8.68% -6.16% -36.14%
Net Income Q/Q Growth		 -1.82% 4.51% -4.33% -27.69% 27.23% -1.51% -3.18% -3.58% -6.99% -35.92%
EPS Q/Q Growth		 1.56% 8.13% -4.01% -28.35% 30.07% 2.33% 2.70% -2.01% -4.90% -34.69%
Operating Cash Flow Q/Q Growth		 1.05% 1.34% -10.45% 2.34% 6.76% -4.92% 8.20% -15.54% -4.71% -35.89%
Free Cash Flow Firm Q/Q Growth		 1.62% 4.06% -192.68% 46.31% -237.43% 87.90% 40.85% -99.07% -2.76% -36.80%
Invested Capital Q/Q Growth		 -2.52% -1.05% -0.56% -18.73% 74.78% -152.00% -6.46% 524.54% -36.50% -23.69%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 86.30% 89.59% 92.21% 95.44% 97.74% 91.31% 97.77% 99.96% 100.00% 0.00%
EBITDA Margin		 -92.29% -128.12% -173.28% -103.46% -116.74% -407.50% -368.47% -12,055.17% -181,475.19% 0.00%
Operating Margin		 -95.67% -131.08% -178.60% -108.63% -121.80% -408.98% -721.18% -12,593.49% -186,471.43% 0.00%
EBIT Margin		 -96.38% -131.16% -179.03% -109.11% -121.58% -409.74% -401.28% -12,343.49% -187,690.23% 0.00%
Profit (Net Income) Margin		 -101.60% -139.70% -194.71% -129.20% -68.84% -388.31% -383.75% -11,567.34% -184,867.67% 0.00%
Tax Burden Percent		 100.28% 99.70% 100.81% 100.23% 100.65% 100.82% 100.26% 94.91% 100.01% 100.00%
Interest Burden Percent		 105.12% 106.83% 107.88% 118.14% 56.25% 94.00% 95.38% 98.74% 98.48% 98.43%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,395.24% -180.41% -413.53% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,377.90% -198.12% -394.26% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 1,331.45% 140.58% 343.06% 0.00% 0.00%
Return on Equity (ROE)		 -211.71% -193.23% -110.96% -43.72% -20.64% -63.79% -39.83% -70.48% -48.93% -40.67%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -187.50% -285.55% 0.00% 0.00%
Operating Return on Assets (OROA)		 -36.06% -37.51% -42.41% -23.37% -22.76% -45.82% -34.15% -62.52% -45.38% 0.00%
Return on Assets (ROA)		 -38.02% -39.96% -46.12% -27.67% -12.89% -43.42% -32.65% -58.59% -44.70% 0.00%
Return on Common Equity (ROCE)		 -208.95% -193.23% -110.96% -43.72% -20.64% -63.79% -39.83% -70.48% -48.93% -40.67%
Return on Equity Simple (ROE_SIMPLE)		 -222.95% -220.26% -200.69% -49.21% -16.16% -61.60% -32.45% -78.79% -51.88% -27.42%
Net Operating Profit after Tax (NOPAT)		 -375 -398 -454 -267 -231 -297 -260 -230 -174 -103
NOPAT Margin		 -66.97% -91.76% -125.02% -76.04% -85.26% -286.29% -504.83% -8,815.44% -130,530.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -25.49% -24.88% -26.23% -16.63% 4.51% -17.34% 17.71% -19.27% -13.90% -11.61%
Return On Investment Capital (ROIC_SIMPLE)		 -146.96% -144.67% -128.87% - - - - - - -
Cost of Revenue to Revenue		 13.70% 10.41% 7.79% 4.56% 2.26% 8.69% 2.23% 0.04% 0.00% 0.00%
SG&A Expenses to Revenue		 57.41% 71.34% 76.55% 62.60% 67.50% 155.74% 248.03% 3,825.00% 48,824.06% 0.00%
R&D to Revenue		 124.57% 149.33% 194.26% 141.48% 152.04% 344.56% 570.93% 8,868.45% 137,747.37% 0.00%
Operating Expenses to Revenue		 181.97% 220.67% 270.81% 204.08% 219.54% 500.30% 818.96% 12,693.45% 186,571.43% 0.00%
Earnings before Interest and Taxes (EBIT)		 -540 -570 -650 -383 -330 -425 -207 -322 -250 -148
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -517 -556 -630 -364 -316 -423 -190 -315 -241 -141
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 15.22 14.26 9.21 6.21 7.32 3.77 3.61 5.15 6.06 8.20
Price to Tangible Book Value (P/TBV)		 119.25 60.66 21.95 7.67 8.63 5.14 5.05 10.00 6.06 8.20
Price to Revenue (P/Rev)		 6.93 9.04 8.94 16.31 31.18 23.79 42.71 756.23 21,600.43 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 11.66 12.45 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.62 7.25 6.47 13.37 26.71 16.46 33.78 662.64 17,844.62 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -2.83 -2.67 -1.51 -1.08 -1.09 -0.97 -0.71 -0.87 -1.03 -1.02
Leverage Ratio		 5.57 4.84 2.41 1.58 1.60 1.47 1.22 1.20 1.09 1.06
Compound Leverage Factor		 5.85 5.17 2.60 1.87 0.90 1.38 1.16 1.19 1.08 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 2.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.33% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.24 -1.85 -1.56 3.76 7.38 0.95 9.79 6.99 23.72 91.10
Noncontrolling Interest Sharing Ratio		 1.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.37 2.61 3.38 4.72 6.83 8.24 6.99 3.80 6.67 16.13
Quick Ratio		 2.13 2.32 3.02 4.24 6.46 7.63 6.32 3.37 6.31 15.65
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -394 -441 -21 -213 -280 -41 -270 -397 -153 -99
Operating Cash Flow to CapEx		 -5,529.14% -1,072.60% -327.64% -463.38% -301.15% -1,390.88% -7,128.70% -9,088.54% -1,580.05% -2,138.79%
Free Cash Flow to Firm to Interest Expense		 -6.25 -6.68 -0.50 -7.25 -8.41 -36.19 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -6.57 -7.19 -8.84 -11.51 -3.97 -304.30 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -6.69 -7.86 -11.54 -14.00 -5.29 -326.18 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.37 0.29 0.24 0.21 0.19 0.11 0.09 0.01 0.00 0.00
Accounts Receivable Turnover		 5.74 7.63 10.55 13.64 9.69 4.55 5.75 0.00 0.00 0.00
Inventory Turnover		 1.94 1.49 1.32 1.09 0.50 0.97 0.29 0.00 0.00 0.00
Fixed Asset Turnover		 2.01 1.58 1.81 3.27 4.60 3.22 2.46 0.13 0.01 0.00
Accounts Payable Turnover		 1.90 1.06 0.94 1.07 0.48 0.72 0.11 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 63.59 47.84 34.60 26.76 37.67 80.21 63.48 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 187.85 245.18 277.08 333.80 732.32 377.05 1,245.65 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 192.35 344.69 389.31 342.71 768.05 509.45 3,369.88 2,600,625.00 0.00 0.00
Cash Conversion Cycle (CCC)		 59.08 -51.68 -77.63 17.84 1.93 -52.19 -2,060.75 -2,600,625.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -483 -502 -544 -111 -58 -107 149 139 -28 -7.45
Invested Capital Turnover		 -1.14 -0.83 -1.11 -4.15 -3.30 4.87 0.36 0.05 -0.01 0.00
Increase / (Decrease) in Invested Capital		 19 43 -433 -54 49 -256 10 167 -20 -4.17
Enterprise Value (EV)		 3,147 3,150 2,351 4,698 7,238 1,707 1,739 1,731 2,373 3,820
Market Capitalization		 3,885 3,927 3,248 5,732 8,450 2,467 2,199 1,975 2,873 4,356
Book Value per Share		 $2.76 $3.35 $5.03 $13.53 $18.91 $11.32 $12.04 $9.00 $11.60 $13.68
Tangible Book Value per Share		 $0.35 $0.79 $2.11 $10.96 $16.04 $8.31 $8.61 $4.64 $11.60 $13.68
Total Capital		 262 275 352 923 1,154 654 609 383 474 531
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -745 -777 -897 -1,034 -1,212 -760 -460 -244 -500 -536
Capital Expenditures (CapEx)		 7.49 44 116 73 44 25 4.08 2.79 10 4.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -137 -125 -125 -65 -96 -7.51 -12 -36 -40 -15
Debt-free Net Working Capital (DFNWC)		 473 452 623 675 1,106 748 448 199 341 422
Net Working Capital (NWC)		 473 452 623 675 1,106 748 448 199 341 422
Net Nonoperating Expense (NNE)		 194 208 253 187 -45 106 -62 72 72 42
Net Nonoperating Obligations (NNO)		 -745 -777 -897 -1,034 -1,212 -760 -460 -244 -502 -539
Total Depreciation and Amortization (D&A)		 23 13 21 20 13 2.33 17 7.53 8.27 7.02
Debt-free, Cash-free Net Working Capital to Revenue		 -24.46% -28.89% -34.42% -18.49% -35.36% -7.24% -23.42% -1,375.34% -30,167.67% 0.00%
Debt-free Net Working Capital to Revenue		 84.42% 104.03% 171.38% 192.15% 407.96% 720.94% 869.30% 7,602.18% 256,718.80% 0.00%
Net Working Capital to Revenue		 84.42% 104.03% 171.38% 192.15% 407.96% 720.94% 869.30% 7,602.18% 256,718.80% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($6.29) ($8.25) ($10.12) ($6.70) ($3.07) ($7.12) ($3.97) ($7.12) ($6.21) ($3.96)
Adjusted Weighted Average Basic Shares Outstanding		 90.54M 73.54M 69.91M 69.38M 66.95M 57.89M 51.28M 49.61M 41.73M 38.98M
Adjusted Diluted Earnings per Share		 ($6.29) ($8.25) ($10.12) ($6.70) ($3.07) ($7.12) ($3.97) ($7.12) ($6.21) ($3.96)
Adjusted Weighted Average Diluted Shares Outstanding		 90.54M 73.54M 69.91M 69.38M 66.95M 57.89M 51.28M 49.61M 41.73M 38.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($6.70) ($3.07) ($7.12) ($3.97) ($7.12) ($6.21) ($3.96)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 92.50M 82.34M 70.22M 67.80M 60.85M 56.58M 49.78M 42.45M 39.59M 36.78M
Normalized Net Operating Profit after Tax (NOPAT)		 -375 -398 -454 -267 -231 -297 -260 -230 -174 -103
Normalized NOPAT Margin		 -66.97% -91.76% -125.02% -76.04% -85.26% -286.29% -504.83% -8,815.44% -130,530.00% 0.00%
Pre Tax Income Margin		 -101.31% -140.12% -193.14% -128.91% -68.39% -385.14% -382.75% -12,187.52% -184,841.35% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -8.56 -8.63 -15.12 -13.03 -9.90 -374.41 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -5.95 -6.04 -10.56 -9.08 -6.94 -261.60 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -8.68 -9.30 -17.82 -15.52 -11.22 -396.29 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -6.07 -6.71 -13.26 -11.57 -8.26 -283.48 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Ultragenyx Pharmaceutical

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 27.99% 29.42% 42.27% 35.75% 8.30% 23.27% 8.10% 21.23% 25.72% 23.93% 11.09%
EBITDA Growth		 16.69% -3.35% 12.75% 24.04% -6.80% 18.58% 35.93% -8.24% -16.26% -46.04% -159.31%
EBIT Growth		 14.88% -4.90% 11.58% 21.18% -8.55% 17.49% 35.54% -5.21% -12.80% -41.25% -150.62%
NOPAT Growth		 13.55% -0.19% 9.04% 21.35% -7.30% 16.19% 35.53% -4.49% -12.79% -41.99% -150.55%
Net Income Growth		 11.49% -8.28% 16.37% 17.66% -4.09% 18.86% 34.87% -1.05% -7.65% -23.99% -235.77%
EPS Growth		 22.66% 6.94% 37.22% 32.44% 12.88% 33.64% 36.29% 0.44% -6.39% -21.91% -224.07%
Operating Cash Flow Growth		 12.72% 5.25% 43.16% 33.74% -21.59% 7.13% -23.63% -50.36% -33.48% -66.24% -59.84%
Free Cash Flow Firm Growth		 37.47% 18.30% 19.32% -136.94% -149.90% -138.69% -150.48% 305.87% 282.05% 1,941.31% 246.61%
Invested Capital Growth		 3.88% 3.78% 5.16% 10.65% 14.20% 7.82% 8.26% -1,665.62% -2,765.65% -388.14% -476.35%
Revenue Q/Q Growth		 -15.52% 18.20% -5.12% 35.09% -14.57% 29.92% -9.47% 7.77% -2.76% 13.94% 1.52%
EBITDA Q/Q Growth		 -12.74% 2.97% -9.79% 30.64% -39.86% 18.08% 4.41% 2.48% -6.62% 35.54% -61.48%
EBIT Q/Q Growth		 -12.88% 2.35% -9.07% 29.21% -39.12% 17.69% 2.77% 2.50% -5.74% 35.69% -58.69%
NOPAT Q/Q Growth		 -16.90% 7.36% -13.43% 29.63% -35.48% 15.88% 1.93% 3.99% -5.82% 35.30% -58.95%
Net Income Q/Q Growth		 -13.27% 0.10% -1.46% 22.90% -38.55% 22.84% 0.11% 2.53% -8.00% 38.05% -54.97%
EPS Q/Q Growth		 -17.16% 4.29% 7.89% 25.12% -40.97% 35.43% 0.89% 3.43% -7.37% 38.00% -54.87%
Operating Cash Flow Q/Q Growth		 -109.39% -18.67% 12.95% 59.65% -127.32% 28.82% -1.47% 25.95% -73.64% 5.25% -23.41%
Free Cash Flow Firm Q/Q Growth		 -11.61% 11.40% 12.04% 28.11% -45.83% 12.51% -140.27% -2.89% 13.05% 14.17% 264.24%
Invested Capital Q/Q Growth		 14.70% -2.52% -6.51% -3.19% 14.61% -1.05% -0.35% 0.90% 8.26% -0.56% -1,831.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 79.42% 89.75% 84.93% 85.53% 83.89% 90.54% 88.79% 90.85% 87.80% 94.85% 90.48%
EBITDA Margin		 -96.81% -72.55% -88.37% -76.36% -148.73% -90.85% -144.09% -136.47% -150.81% -137.54% -243.11%
Operating Margin		 -102.62% -74.16% -94.62% -79.14% -151.93% -95.81% -147.98% -136.61% -153.34% -140.91% -248.14%
EBIT Margin		 -102.02% -76.35% -92.41% -80.39% -153.40% -94.20% -148.69% -138.44% -153.04% -140.74% -249.35%
Profit (Net Income) Margin		 -108.46% -80.90% -95.71% -89.51% -156.83% -96.70% -162.82% -147.57% -163.16% -146.91% -270.23%
Tax Burden Percent		 100.87% 99.99% 100.23% 100.66% 100.27% 97.08% 100.41% 100.46% 100.30% 99.05% 102.63%
Interest Burden Percent		 105.40% 105.97% 103.34% 110.62% 101.96% 105.74% 109.06% 106.10% 106.29% 105.39% 105.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -377.06% -211.71% -289.98% -208.43% -340.05% -193.23% -253.84% -178.60% -141.42% -110.96% -96.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -46.02% -28.57% -34.80% -26.41% -50.47% -26.94% -42.70% -42.38% -42.46% -33.34% -55.18%
Return on Assets (ROA)		 -48.93% -30.27% -36.04% -29.41% -51.60% -27.66% -46.76% -45.17% -45.27% -34.80% -59.80%
Return on Common Equity (ROCE)		 -368.00% -208.95% -284.71% -208.43% -340.05% -193.23% -253.84% -178.60% -141.42% -110.96% -96.69%
Return on Equity Simple (ROE_SIMPLE)		 -381.00% 0.00% -161.17% -135.31% -437.28% 0.00% -2,003.16% -558.58% -326.14% 0.00% -144.63%
Net Operating Profit after Tax (NOPAT)		 -100 -86 -92 -81 -116 -85 -102 -104 -108 -102 -158
NOPAT Margin		 -71.83% -51.91% -66.23% -55.40% -106.35% -67.06% -103.59% -95.62% -107.34% -98.64% -173.69%
Net Nonoperating Expense Percent (NNEP)		 -9.02% -6.28% -6.08% -6.69% -8.53% -4.51% -7.55% -8.46% -7.32% -5.17% -8.59%
Return On Investment Capital (ROIC_SIMPLE)		 -69.37% -33.53% - - - -31.02% - - - -28.92% -
Cost of Revenue to Revenue		 20.58% 10.25% 15.07% 14.47% 16.11% 9.46% 11.21% 9.15% 12.20% 5.15% 9.52%
SG&A Expenses to Revenue		 63.03% 50.03% 57.60% 54.82% 71.82% 60.31% 76.41% 75.16% 76.27% 70.49% 77.00%
R&D to Revenue		 119.01% 113.88% 121.95% 109.85% 164.00% 126.03% 160.37% 152.29% 164.88% 165.27% 261.62%
Operating Expenses to Revenue		 182.04% 163.92% 179.55% 164.67% 235.82% 186.35% 236.77% 227.45% 241.15% 235.76% 338.62%
Earnings before Interest and Taxes (EBIT)		 -142 -126 -129 -118 -167 -120 -146 -150 -154 -145 -226
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -135 -120 -123 -112 -162 -116 -141 -148 -152 -142 -221
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 23.22 15.22 14.76 7.90 27.33 14.26 80.36 25.32 12.77 9.21 6.19
Price to Tangible Book Value (P/TBV)		 0.00 119.25 37.24 15.41 0.00 60.66 0.00 0.00 166.57 21.95 10.90
Price to Revenue (P/Rev)		 5.67 6.93 9.79 7.10 8.66 9.04 6.21 8.11 7.33 8.94 8.45
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 4.73 5.62 8.23 5.28 7.38 7.25 4.93 6.56 5.46 6.47 5.50
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 136.23 0.00 81.49
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.88 -2.83 -3.51 -2.67 -3.57 -2.67 -3.07 -1.65 -1.51 -1.51 -1.45
Leverage Ratio		 8.98 5.57 7.20 5.22 7.46 4.84 5.71 3.26 2.72 2.41 2.21
Compound Leverage Factor		 9.47 5.90 7.44 5.77 7.60 5.11 6.22 3.46 2.89 2.54 2.34
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 4.63% 2.67% 1.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.37% 97.33% 98.02% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.19 -1.33 -0.42 -0.89 -1.60 -0.85 -2.15 -1.31 -1.14 -0.48 -0.43
Noncontrolling Interest Sharing Ratio		 2.40% 1.30% 1.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.40 2.37 2.81 3.54 2.43 2.61 2.36 2.87 3.51 3.38 4.45
Quick Ratio		 2.03 2.13 2.51 3.19 2.09 2.32 2.05 2.55 3.08 3.02 4.05
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -117 -105 -118 -134 -187 -128 -146 363 374 331 290
Operating Cash Flow to CapEx		 -12,573.64% -12,156.42% -4,143.17% -3,830.91% -5,939.80% -5,244.00% -3,190.09% -833.41% -626.62% -334.97% -366.06%
Free Cash Flow to Firm to Interest Expense		 -8.14 -6.74 -7.51 -8.41 -11.78 -7.39 -8.28 23.62 23.92 20.84 19.98
Operating Cash Flow to Interest Expense		 -11.61 -5.12 -4.26 -4.82 -12.04 -4.84 -6.67 -7.56 -10.03 -5.69 -6.57
Operating Cash Flow Less CapEx to Interest Expense		 -11.70 -5.16 -4.37 -4.95 -12.24 -4.93 -6.88 -8.46 -11.63 -7.39 -8.37
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.37 0.38 0.33 0.33 0.29 0.29 0.31 0.28 0.24 0.22
Accounts Receivable Turnover		 5.93 5.74 6.06 5.45 6.18 7.63 7.43 7.48 10.76 10.55 12.14
Inventory Turnover		 2.14 1.94 1.91 1.81 1.61 1.49 1.43 1.46 1.55 1.32 1.43
Fixed Asset Turnover		 2.16 2.01 1.84 1.70 1.57 1.58 1.54 1.62 1.69 1.81 1.94
Accounts Payable Turnover		 1.99 1.90 2.07 1.21 1.01 1.06 1.35 0.95 0.83 0.94 1.36
Days Sales Outstanding (DSO)		 61.51 63.59 60.25 66.93 59.07 47.84 49.13 48.80 33.92 34.60 30.05
Days Inventory Outstanding (DIO)		 170.20 187.85 190.75 201.80 226.02 245.18 254.47 249.26 235.16 277.08 254.99
Days Payable Outstanding (DPO)		 183.67 192.35 176.06 300.74 361.32 344.69 269.83 385.64 437.58 389.31 269.23
Cash Conversion Cycle (CCC)		 48.04 59.08 74.94 -32.01 -76.24 -51.68 33.77 -87.58 -168.50 -77.63 15.82
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -412 -483 -471 -442 -428 -502 -496 -495 -499 -544 -541
Invested Capital Turnover		 -1.41 -1.14 -1.08 -1.03 -0.95 -0.83 -0.79 -1.54 -1.49 -1.11 -1.08
Increase / (Decrease) in Invested Capital		 17 19 26 53 71 43 45 -467 -482 -433 -447
Enterprise Value (EV)		 2,793 3,147 4,302 2,542 3,265 3,150 2,020 2,643 2,096 2,351 1,890
Market Capitalization		 3,349 3,885 5,120 3,417 3,834 3,927 2,549 3,267 2,816 3,248 2,900
Book Value per Share		 $1.56 $2.76 $3.76 $5.20 $1.66 $3.35 $0.44 $1.82 $3.14 $5.03 $6.69
Tangible Book Value per Share		 ($0.83) $0.35 $1.49 $2.67 ($0.82) $0.79 ($2.38) ($1.04) $0.24 $2.11 $3.80
Total Capital		 151 262 354 432 140 275 32 129 220 352 469
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -563 -745 -825 -874 -569 -777 -528 -624 -720 -897 -1,010
Capital Expenditures (CapEx)		 1.32 0.65 1.62 2.01 3.21 1.60 3.70 14 25 27 26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -87 -137 -107 -72 -62 -125 -97 -94 -81 -125 -103
Debt-free Net Working Capital (DFNWC)		 407 473 515 692 350 452 345 458 548 623 785
Net Working Capital (NWC)		 407 473 515 692 350 452 345 458 548 623 785
Net Nonoperating Expense (NNE)		 51 48 41 50 55 38 58 56 56 50 88
Net Nonoperating Obligations (NNO)		 -563 -745 -825 -874 -569 -777 -528 -624 -720 -897 -1,010
Total Depreciation and Amortization (D&A)		 7.26 6.27 5.64 5.92 5.09 4.27 4.51 2.14 2.24 3.31 5.66
Debt-free, Cash-free Net Working Capital to Revenue		 -14.72% -24.46% -20.47% -14.97% -13.94% -28.89% -23.62% -23.39% -21.15% -34.42% -30.10%
Debt-free Net Working Capital to Revenue		 68.99% 84.42% 98.44% 143.73% 79.17% 104.03% 84.16% 113.63% 142.79% 171.38% 228.71%
Net Working Capital to Revenue		 68.99% 84.42% 98.44% 143.73% 79.17% 104.03% 84.16% 113.63% 142.79% 171.38% 228.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.57) ($1.34) ($1.40) ($1.52) ($2.03) ($1.44) ($2.23) ($2.25) ($2.33) ($2.17) ($3.50)
Adjusted Weighted Average Basic Shares Outstanding		 96.29M 90.54M 95.49M 86.58M 84.29M 73.54M 71.66M 70.90M 70.37M 69.91M 70.05M
Adjusted Diluted Earnings per Share		 ($1.57) ($1.34) ($1.40) ($1.52) ($2.03) ($1.44) ($2.23) ($2.25) ($2.33) ($2.17) ($3.50)
Adjusted Weighted Average Diluted Shares Outstanding		 96.29M 90.54M 95.49M 86.58M 84.29M 73.54M 71.66M 70.90M 70.37M 69.91M 70.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 94.54M 92.50M 92.34M 92.17M 83.13M 82.34M 82.11M 71.49M 70.81M 70.22M 70.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -100 -86 -92 -81 -116 -85 -102 -104 -108 -102 -158
Normalized NOPAT Margin		 -71.83% -51.91% -66.23% -55.40% -106.35% -67.06% -103.59% -95.62% -107.34% -98.64% -173.69%
Pre Tax Income Margin		 -107.52% -80.91% -95.50% -88.92% -156.41% -99.61% -162.16% -146.89% -162.67% -148.32% -263.30%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -9.91 -8.11 -8.20 -7.41 -10.54 -6.93 -8.25 -9.75 -9.84 -9.16 -15.59
NOPAT to Interest Expense		 -6.98 -5.51 -5.88 -5.10 -7.30 -4.93 -5.75 -6.74 -6.90 -6.42 -10.86
EBIT Less CapEx to Interest Expense		 -10.00 -8.15 -8.31 -7.53 -10.74 -7.02 -8.46 -10.66 -11.44 -10.86 -17.39
NOPAT Less CapEx to Interest Expense		 -7.07 -5.56 -5.98 -5.23 -7.51 -5.02 -5.96 -7.64 -8.50 -8.12 -12.66
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

When does Ultragenyx Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Ultragenyx Pharmaceutical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ultragenyx Pharmaceutical's net income changed over the last 9 years?

Ultragenyx Pharmaceutical's net income appears to be on an upward trend, with a most recent value of -$569.18 million in 2024, rising from -$145.62 million in 2015. The previous period was -$606.64 million in 2023. View Ultragenyx Pharmaceutical's forecast to see where analysts expect Ultragenyx Pharmaceutical to go next.

What is Ultragenyx Pharmaceutical's operating income?
Ultragenyx Pharmaceutical's total operating income in 2024 was -$535.97 million, based on the following breakdown:
  • Total Gross Profit: $483.50 million
  • Total Operating Expenses: $1.02 billion
How has Ultragenyx Pharmaceutical revenue changed over the last 9 years?

Over the last 9 years, Ultragenyx Pharmaceutical's total revenue changed from $0.00 in 2015 to $560.23 million in 2024, a change of 56,023,000,000.0%.

How much debt does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical's total liabilities were at $1.24 billion at the end of 2024, a 2.1% increase from 2023, and a 4,258.2% increase since 2015.

How much cash does Ultragenyx Pharmaceutical have?

In the past 9 years, Ultragenyx Pharmaceutical's cash and equivalents has ranged from $93.57 million in 2015 to $713.53 million in 2020, and is currently $173.73 million as of their latest financial filing in 2024.

How has Ultragenyx Pharmaceutical's book value per share changed over the last 9 years?

Over the last 9 years, Ultragenyx Pharmaceutical's book value per share changed from 13.68 in 2015 to 2.76 in 2024, a change of -79.8%.


Related Companies

This page (NASDAQ:RARE) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored